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Abstract
Objective—Long bones develop through the strictly regulated process of endochondral
ossification within the growth plate, resulting in the replacement of cartilage by bone. Defects in
this process result in skeletal abnormalities and can predispose to disease such as osteoarthritis
(OA). Studies suggest that activation of the transcription factor peroxisome proliferator activated
receptor gamma (PPARγ) is a therapeutic target for OA. In order to devise PPARγ-related
therapies in OA and related diseases, it is critical to identify its role in cartilage biology.
Therefore, we determined the in vivo role of PPARγ in endochondral ossification and cartilage
development using cartilage-specific PPARγ knockout (KO) mice.
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Methods—Cartilage-specific PPARγ KO mice were generated using LoxP/Cre system.
Histomorphometric and immunohistochemical analysis was performed to account for ossification
patterns, chondrocyte proliferation, differentiation, hypertrophy, skeletal organization, bone
density and calcium deposition. Real-Time PCR and western blotting was performed to determine
the expression of key markers involved in endochondral ossification.
Results—PPARγ KO mice exhibited reduced body length, weight, length of long bones, skeletal
growth, cellularity, bone density, calcium deposition and trabecular bone thickness, abnormal
growth plate organization, loss of columnar organization, shorter hypertrophic zones, and delayed
primary and secondary ossification. Immunohistochemistry for Sox9, BrdU, p57, collagen X and
PECAM revealed reduction in chondrocyte differentiation and proliferation, and hypertrophy and
vascularisation in growth plates of mutant mice. Isolated chondrocytes and cartilage explants from
mutant mice showed aberrant expression of ECM markers including aggrecan, collagen II and
MMP-13.
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Conclusion—PPARγ is required for normal endochondral ossification and cartilage
development in vivo.
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INTRODUCTION
Long bones are formed and lengthened through a process termed endochondral ossification
whereby a cartilage anlagen grows through chondrocyte proliferation and hypertrophy [1]
and, subsequently, cartilage is replaced by bone [2]. In this process, cartilage provides an
intermediate template on which bone is laid down [3]. During endochondral bone growth,
chondrocytes are organized into three zones within the epiphyses of the cartilage, namely,
resting, proliferating, and hypertrophic zones. Resting and proliferating chondrocytes
express high levels of aggrecan and collagen type II, the two main components of the
cartilage extracellular matrix (ECM), while hypertrophic chondrocytes express collagen type
X. Prior to entering the hypertrophic zone, cells exit the cell cycle and begin to differentiate
to hypertrophic chondrocytes [4]. Subsequently, they mineralize their surrounding ECM in
the cartilage centre and undergo apoptosis [5, 6]. Blood vessels then invade the hypertrophic
cartilage region, bringing in osteoblasts and osteoclasts [6]. Osteoclasts degrade mineralized
cartilage while osteoblasts replace it with bone tissue [1, 2, 7]. This mineralization process is
termed primary ossification [8]. Secondary ossification centres are formed in the epiphyses
post-natally [2].
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The normal lengthening of long bones depends on the rate of production of hypertrophic
chondrocytes from proliferating chondrocytes, the volume increase in hypertrophic
chondrocytes, and the number of proliferative cycles a chondrocyte undergoes [4, 9–12].
Disturbances in the fine balance controlling endochondral bone growth result in growth- and
development-related abnormalities such as dwarfism and skeletal deformities. Several other
signaling molecules, including Indian hedgehog, fibroblast growth factors (FGFs), Akt, and
Wnt/β-catenin have been shown to play roles in chondrogenesis and cartilage growth and
development [13–16] (Reviewed in [12]). However, the exact mechanisms through which
chondrocyte function and behaviour is controlled during chondrogenesis and cartilage
growth and development are largely unknown. A better understanding of chondrogenesis
and cartilage growth and development will help to advance our knowledge of the
pathophysiology of diseases such as OA.
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The transcription factor peroxisome proliferator-activated receptor gamma (PPARγ)
belongs to the family of ligand-activated nuclear receptors and plays a key role in lipid and
glucose homeostasis [17, 18]. It regulates gene expression by binding as a heterodimer to
retinoid X receptor. This heterodimer complex acts as a transcriptional regulator upon
binding to sequence-specific PPAR response elements in the promoter region of target genes
[17, 18]. Recent studies suggest that PPARγ is involved in the maintenance of bone
homeostasis by contributing to osteoclastogenic and osteoblastogenic pathways. Mice
lacking PPARγ in osteoclasts develop osteopetrosis, which results from impaired osteoclast
differentiation [19]. In addition, in vitro studies suggest that PPARγ may play a role in
chondrocyte biology [20]. However, the specific in vivo role of PPARγ in chondrogenesis
and cartilage growth and development is still largely unknown. Therefore, this study
examined, for the first time, the specific in vivo contribution of PPARγ to chondrogenesis
and cartilage growth and development using cartilage-specific PPARγ knockout (KO) mice,
as global PPARγ KO mice exhibit embryonic lethality due to placental defects [21].
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MATERIALS AND METHODS
Materials
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C57BL/6-PPARγfl/fl mice were obtained from Jackson Laboratory (Bar Harbor, Maine).
C57BL/6 Col2-Cre transgenic mice were obtained from Shriners Hospital for Children,
Montreal, QC, Canada [22]. The following antibodies were used in this study: platelet/
endothelial cell adhesion molecule 1 (PECAM-1) #SC-1506, Sox9 #SC-20095, p57
#SC-8298, PPARγ #SC-7273, goat-anti-rabbit #SC-2004, goat-anti-mouse #SC-2005,
rabbit-anti-goat #SC-2768 (Santa Cruz Biotechnology, Santa Cruz, California); collagen
type X #C-7974, 5-bromo-2'-deoxyuridine (BrdU) #B-8434, Cre #C-7988, MMP-13
#M-4052 (Sigma-Aldrich, Oakville, Ontario); p38 #9212 and phospho-p38 #9216 (Cell
Signaling, Danvers, Massachusetts); DMEM and trypsin/EDTA (Wisent, St-Bruno,
Quebec).
Generation of cartilage-specific PPARγ KO mice
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Genetically modified mice harbouring a cartilage-specific deletion of PPARγ were
generated using the Cre Lox methodology in which mice carrying Cre recombinase under
the control of the collagen type II promoter were used to induce specific recombination in
chondrocytes as previously established [22]. Briefly, mice containing a PPARγ gene
flanked by LoxP sites (C57BL/6-PPARγfl/fl, Jackson Laboratory) were mated with C57BL/
6 Col2-Cre transgenic mice [22–24] to generate mice bearing Col2-Cre and a floxed allele in
their germline (genotype: PPARγfl/+, Cre). These mice were backcrossed to homozygote
floxed mice in the following cross: PPARγfl/+, Cre X PPARγfl/fl to generate mice with both
alleles inactivated in chondrocytes (genotype: PPARγfl/fl, Cre). PPARγfl/fl, Cre mice are
referred to as homozygote PPARγ KO mice, PPARγfl/+ Cre mice are referred to as
heterozygote PPARγ KO mice, and PPARγfl/fl mice without Cre transgene are referred to
as control mice.
All procedures involving animals were approved by the Comité institutionnel de protection
des animaux of the CRCHUM, and the Animal Use Subcommittee of the Canadian Council
on Animal Care at the University of Western Ontario. All animal studies including housing
and breeding were performed as approved by the aforementioned committees. All mice were
kept in a 12 hour light/dark cycle. Food and water were available ad libitum.
Primary culture of chondrocytes
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Primary chondrocytes were prepared from long bones of embryonic day (E) 16.5 control,
heterozygote and homozygote PPARγ KO mice as previously described [25]. Cartilage was
dissected from long bones, rinsed in phosphate buffered saline (PBS), and incubated at 37
°C for 15 minutes in trypsin-EDTA followed by digestion with 2 mg/ml collagenase P at 37
°C for 2 hours in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal
bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin under an atmosphere
of 5% CO2. The cell suspension was filtered through a 70-µm cell strainer (Falcon, Fort
Worth, Texas), washed, counted and plated. At confluence, the cells were detached and
plated for experiments. To retain the phenotype, only first-passage cultured chondrocytes
were used throughout the study.
Western blotting
Cells were lysed in Tris-Buffered Saline (TBS) containing 0.1% sodium dodecyl sulfate
(SDS), and the protein content of the lysates was determined using bicinchoninic acid
protein assay reagent (Thermo Fisher Scientific, Rockford, Illinois) with bovine serum
albumin (BSA) as the standard. Cell lysates were adjusted to equal equivalents of protein
and then were applied to SDS-polyacrylamide gels (10%) for electrophoresis. Next, the
Arthritis Rheum. Author manuscript; available in PMC 2013 May 01.
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proteins were electroblotted onto polyvinylidene fluoride membranes. After the membranes
were blocked in 10mM TBS containing 0.1% Tween-20 (TBS-T) and 5% skim milk, the
membranes were probed for 1.5 hours with the respective primary antibody (anti-PPARγ;
1:1000 dilution) in TBS-T. After washing the membranes with TBS-T, the membranes were
incubated overnight with the appropriate secondary antibody in TBS-T containing 5% skim
milk at 4 °C. After further washing with TBS-T, protein bands were visualized with an
enhanced chemiluminescence system using a Bio-Rad (Mississauga, Ontario) Chemidoc
Apparatus.
RNA isolation and real-time polymerase chain reaction
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Total RNA was isolated from chondrocytes or cartilage explants using TRIzol (Invitrogen,
Burlington, Ontario) and RNeasy (QIAGEN, Toronto, Ontario) according to the
manufacturers’ recommendations, reverse transcribed and amplified using the TaqMan
Assays-on-Demand (Applied Biosystems, Streetsville, Ontario) in a reaction solution
containing two unlabeled primers and a 6-carboxyfluorescein-labeled TaqMan MGB probe
[26, 27]. Samples were combined with One-Step MasterMix (Eurogentec, San Diego,
California). Amplified sequences were detected using the ABI Prism 7900HT sequence
detector (Applied Biosystems) according to the manufacturer’s instructions. The expression
values were standardized to values obtained with control glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) RNA primers using the ΔCt method. All primers and probe sets
were obtained from Applied Biosystems and data were normalized to GAPDH mRNA levels
and represent averages and standard error of the mean (SEM) from direct comparison of KO
and control littermates. Statistical significance of real time polymerase chain reaction
(qPCR) results was determined by two-way analysis of variance with the Bonferroni posttest using GraphPad Prism 3.00 for Windows.
Skeletal staining
Newborn mice were skinned, eviscerated, and dehydrated in 95% ethanol and acetone
overnight. Skeletons were stained with 0.015% alcian blue, 0.05% alizarin red, and 5%
acetic acid in 70% ethanol for several days. Skeletons were then cleared in 1% KOH, passed
through a decreasing KOH series and stored in glycerol/ethanol (1:1) [23, 28].
Histological and immunohistochemistry studies
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Freshly dissected mouse long bones were fixed with 10% neutral buffered formalin and
decalcified with 0.1 M EDTA at room temperature before paraffin embedding and
sectioning at the Centre for Bone and Periodontal Research at McGill University (Montreal,
QC, Canada). Sections (5 µm) were deparaffinized in xylene followed by a graded series of
alcohol washes. Sections were stained with Safranin-O/Fast Green (Sigma-Aldrich,
Oakville, Ontario) according to the manufacturer’s recommendations. For
immunohistochemistry (IHC) analysis, the Dakocytomation (Dako, Burlington, Ontario)
labeled streptavidin biotin + System-horseradish peroxidase kit was used following the
manufacturer’s recommended protocol. Briefly, endogenous peroxide was blocked for 5
minutes using 3% H2O2. Nonspecific immunoglobulin G binding was blocked by incubating
sections with BSA (0.1%) in PBS for 1 hour. Sections were then incubated with the primary
antibody in a humidified chamber and left overnight at 4 °C. Next, sections were incubated
with biotinylated link for 30 minutes followed by streptavidin for 1 hour. The
diaminobenzidine tetrahydrochloride chromogen substrate solution was then added until
sufficient color developed.
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BrdU labeling
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For BrdU labeling, pregnant female mice were injected one day before being sacrificed i.p.
with BrdU at a dose of 0.01 ml/g. BrdU was detected in paraffin sections using an anti-BrdU
antibody through IHC as detailed above.
Bone mineralization
Freshly dissected mouse long bones were fixed with 10% neutral buffered formalin before
plastic embedding, sectioning, and staining at the Centre for Bone and Periodontal Research
at McGill University (Montreal, QC, Canada). Sections (5 µm) were stained with von Kossa
to determine calcium deposition in the bone, Goldner to determine bone density, and
Safranin-O/Fast Green to determine trabecular bone thickness. Bone density and trabecular
bone thickness were quantified using Bioquant Osteo II software as previously described
[29].
Cartilage explant studies
Cartilage explant studies were conducted using femoral head cartilage from 3-week-old
control and homozygote PPARγ KO mice. Cartilage was extracted, rinsed in PBS and RNA
was isolated and subjected to qPCR using specific primers as described above.
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Statistical analysis
Statistical analysis was evaluated by the two-tailed Student’s t-test. P < 0.05 was considered
statistically significant.

RESULTS
Characterization of cartilage-specific PPARγ KO mice

NIH-PA Author Manuscript

Due to the fact that global PPARγ KO mice die as a result of embryonic lethality, the LoxP/
Cre system was used to generate cartilage-specific PPARγ conditional KO mice. Mice
containing a PPARγ gene flanked by LoxP sites (PPARγfl/fl) were mated with mice
carrying Cre recombinase under the control of the collagen type II promoter to induce
specific recombination in chondrocytes [22]. Generation of conditional KO mice was first
determined by tail DNA genotyping, which confirmed the presence of the Cre transgene in
heterozygote (PPARγfl/w Cre) and homozygote (PPARγf/f Cre) PPARγ KO mice and its
absence in WT (wild-type) (control) mice (Figure 1A). Loss of PPARγ expression in
chondrocytes isolated from homozygote and heterozygote PPARγ KO versus control mice
was confirmed by Western blotting (Figure 1B) and qPCR (Figure 1C). Additionally, IHC
studies performed on femurs of post-natal day (P) 0 control mice demonstrated strong
expression of PPARγ in resting and hypertrophic chondrocytes of the growth plate.
However, PPARγ positive chondrocytes were undetectable in the resting and hypertrophic
zones of the growth plate of homozygote PPARγ KO mice, thus confirming that
recombination occurred with high efficiency (Figure 1D).
Cartilage-specific deletion of PPARγ results in reduced growth
We first determined the effect of cartilage-specific ablation of PPARγ on body length, body
weight, and skeletal growth of mice. Analyses of newborn litters demonstrated growth
retardation in homozygote PPARγ KO mice compared to control mice (Figure 2A). Wholemount skeletal staining with alcian blue and alizarin red confirmed that newborn
homozygote PPARγ KO mice show reduced skeletal growth compared to control mice and
skeletal staining in some regions of the limbs in mutant mice was weaker compared to
control mice (Figure 2B). Measurements of growth over 42 days post-birth demonstrated
that homozygote PPARγ KO mice had significantly reduced body length (Figure 2C) and
Arthritis Rheum. Author manuscript; available in PMC 2013 May 01.
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weight (Figure 2D) compared to control mice. Measurements of individual bones
demonstrated that homozygote PPARγ KO mice had significantly reduced length of tibiae
and femurs at time of birth (Figure 2E). No significant differences in the viability of mice
were observed. A consistent pattern of growth and weight retardation was observed in both
genders.
PPARγ-deficient mice show delayed ossification and disorganization of growth plates
We further examined the effect of PPARγ deficiency on the organization of growth plates
and ossification patterns. Histological analysis by Safranin-O/Fast Green staining
demonstrated that femurs of E16.5 homozygote PPARγ KO mice exhibit reduced length
and delayed primary ossification compared to control mice (Figure 3A). In addition, femurs
of P14 homozygote PPARγ KO mice exhibited delayed secondary ossification compared to
control mice (Figure 3B).
Blinded histological analyses were also performed to examine growth plate organization on
a cellular level at time of birth. Safranin-O/Fast Green staining of P0 mouse femurs of
homozygote PPARγ KO mice demonstrated growth plate defects, which is associated with
hypocellularity in all three zones, loss of columnar organization in the proliferating zone,
altered chondrocyte shape in the hypertrophic zone, and a shortened hypertrophic zone
compared to control mice (Figure 3C,D).
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Cartilage-specific deletion of PPARγ results in reduced chondrocyte proliferation,
differentiation, hypertrophy and vascular invasion
Subsequently, we determined if PPARγ deficiency altered chondrocyte differentiation,
proliferation, hypertrophy and vascular invasion. IHC using antibodies against Sox9 (Figure
4A), a marker of early chondrocyte differentiation, BrdU (Figure 4B), a marker of
proliferation, and p57 (Figure 4C), a cell cycle inhibitor required for normal hypertrophic
differentiation, revealed that femurs of E16.5 homozygote PPARγ KO mice exhibit reduced
chondrocyte differentiation and proliferation as demonstrated by a reduced percentage of
positive cells compared to control mice. IHC using collagen type X, a marker of
chondrocyte hypertrophy, demonstrated that the femurs of E16.5 homozygote PPARγ KO
mice exhibit reduced chondrocyte hypertrophy compared to control mice (Figure 4D). IHC
for PECAM, a cell surface marker for endothelial cells and a marker of new blood vessel
formation, further demonstrated reduced vascular invasion in the femurs of E16.5
homozygote PPARγ KO mice compared to control mice (Figure 4E).
Cartilage-specific deletion of PPARγ causes reduced bone density
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We further investigated whether the loss of PPARγ resulted in abnormal calcium deposition
and bone density. Two bone mineralization staining methods, von Kossa (Figure 5A) and
Goldner (Figure 5B), in combination with measurements to quantify bone density (Figure
5C) using Bioquant Osteo II software, demonstrated that P0 homozygote PPARγ KO mouse
femurs exhibit reduced calcium deposition and bone density, respectively, compared to
control mice. Measurements using Bioquant Osteo II software to quantify trabecular bone
thickness in P40 and P70 mice further demonstrated that homozygote PPARγ KO mice
display significantly reduced trabecular bone thickness compared to control mice (Figure
5D).
PPARγ-deficiency results in reduced expression of aggrecan and collagen type II, and
increased expression of MMP-13
We next isolated chondrocytes from E16.5 control and homozygote PPARγ KO mice
(Figure 6A), and femur head cartilage explants from 3-week-old control and homozygote
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PPARγ KO mice (Figure 6B) and examined the expression of the ECM proteins, aggrecan
and collagen type II, and the catabolic factor MMP-13. Our analyses indicated that
homozygote PPARγ KO mouse chondrocytes and cartilage explants exhibit significantly
reduced expression of aggrecan and collagen type II, and significantly increased expression
of MMP-13 compared to control mouse chondrocytes and cartilage explants.

DISCUSSION
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Our results, for the first time, demonstrate an important in vivo role of PPARγ in
endochondral ossification and cartilage growth and development through the use of
cartilage-specific PPARγ KO mice. We show that genetic ablation of PPARγ in cartilage in
vivo results in marked alterations in the process of endochondral ossification, and cartilage
and long bone development, with specific alterations at the tissue, cellular, and molecular
levels. PPARγ deficiency caused reduced growth and skeletal size, shorter length of long
bones, delayed primary and secondary ossification, disorganization of growth plates
accompanied by hypocellularity, reduced chondrocyte proliferation, differentiation and
hypertrophy, delayed vascular invasion, decreased bone density, calcium deposition and
trabecular bone thickness, and aberrant expression of key markers involved in
skeletogenesis (Sox9, p57, and collagen type X) as well as ECM synthesis (aggrecan and
collagen type II) and degradation (MMP-13) products. Collectively, our results demonstrate
that PPARγ plays a pivotal role in coordinating diverse aspects of skeletal morphogenesis.
As demonstrated by skeletal staining and measurements, cartilage-specific deletion of
PPARγ resulted in abnormal endochondral bone growth, including reduced body size in
terms of height and weight as well as reduced skeletal size and length of long bones.
Histological analyses further revealed that PPARγ deficiency caused delayed primary and
secondary ossification and disorganization of the growth plates. All three zones of the
cartilage epiphyses of mutant mice showed signs of highly disorganized growth plates,
including hypocellularity and reduced chondrocyte proliferation, differentiation and
hypertrophy. Since the normal lengthening of long bones depends on the rate of production
of hypertrophic chondrocytes from proliferating chondrocytes, the increased volume of
hypertrophic chondrocytes, and the number of proliferative cycles a chondrocyte undergoes
[9–12], improper coordination of these variables results in abnormal bone length by
hindering mineralization, apoptosis, vascular invasion, and thus, overall endochondral bone
development.
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Some of the key essential factors required for normal ossification, ECM production, and
vascularization processes during early development of cartilage and bone include Sox9, p57,
aggrecan, collagen type II, and collagen type X. During chondrogenesis, chondrocytes begin
expressing Sox9, a chondrogenic transcription factor that is essential for proliferation and
differentiation of chondrocytes. Within the growth plate, Sox9 is expressed in resting and
proliferating chondrocytes and regulates the expression of genes encoding aggrecan and
collagen type II, the two main components of the cartilage ECM [30–32]. p57 is a cell cycle
inhibitor essential for cell cycle exit and onset of hypertrophic differentiation. Collagen type
X is a cartilage ECM component unique to the hypertrophic zone and serves as a marker of
terminally differentiated hypertrophic chondrocytes [33]. In the final step of endochondral
bone development, chondrocytes undergo hypertrophy and produce a calcified, cartilaginous
ECM, and angiogenic factors, which initiate and propagate vascular invasion. As a result,
avascular cartilage is replaced by densely vascularized bone.
Delayed ossification and growth plate abnormalities in PPARγ mutant mice can be
explained by the abnormal expression of Sox9, p57, and collagen type X. Our results show
that the growth plates of homozygote PPARγ KO mice exhibit significantly reduced
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expression of Sox9 and p57, thus affecting the normal sequence of chondrocyte
proliferation, differentiation, and hypertrophy. In addition, the growth plates of homozygote
PPARγ KO mice exhibit significantly reduced expression of PECAM, indicating delayed
vascularization. Growth plates of homozygote PPARγ KO mice showed reduced expression
of collagen type X. Collagen type X facilitates endochondral ossification by regulating
matrix mineralization and compartmentalizing matrix components [34]. Mice with altered
collagen type X function exhibit skeletal defects including compressed growth plates with
reduced proliferative and hypertrophic zones, and trabecular bone thickness [35–37].
Therefore, reduced length of long bones, bone density and trabecular bone thickness may in
part be dependent on decreased collagen type X expression upon genetic deletion of
PPARγ.
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We have previously observed a close relationship between PPARγ and p38 signalling. We
have shown that PPARγ expression is suppressed by p38 activity. We examined show that
PPARγ deficient chondrocytes (E16.5) show increased phosphorylation of p-38 and
reduction in the mRNA expression of Indian Hedgehog (Ihh). Previous study using
transgenic mice that specifically expresses a constitutively active mutant of MKK6 in
chondrocytes that specifically activates p38 results in mice exhibiting a dwarf phenotype
associated with reduction in chondrocyte proliferation, inhibition of hypertrophic
chondrocyte differentiation, and a delay in primary and secondary ossification (Zhang et al.,
2006 PNAS), a similar phenotype we observe with PPARγ-deficient mice. Ihh is a key
regulator of normal endochondral bone and skeletal development (St-Jacques et al., 1999,
Genes & Dev). We and others have shown that p38 negatively regulates the expression of
Ihh both in vitro (Stanton and Beier, 2007, Exp. Cell Res) and in vivo (Zhang et al., 2006
PNAS). Here we show that PPARγ deficient chondrocytes exhibit decreased expression of
Ihh, suggesting that inactivation of PPARγ and subsequent increase in the phosphorylation
of p38 may account for repression of Ihh and ultimately contributing towards abnormal
endochondral ossification observed in PPARγ-deficient mice.
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It should be mentioned that previous studies have shown that PPARγ activation suppresses
collagen type X expression and other markers of hypertrophic chondrocyte differentiation
[20, 38]. At first glance, this appears to be contradictory to the delay in hypertrophic
differentiation upon inactivation of PPARγ that we observed here. However, several
possibilities could explain these apparent discrepancies. First, it is possible that there is an
optimal level of PPARγ activity to promote hypertrophy and that both overactivation and
inactivation suppress this process. Second, it is possible that reduced hypertrophy in these
two settings is due to different mechanisms; PPARγ activation might directly suppress
hypertrophy, while the smaller hypertrophic zone in cartilage-specific PPARγ KO mice
could be secondary to reduced chondrocyte proliferation (e.g. less cells entering the
hypertrophic zone). Further studies will be required to decipher the mechanisms involved.
In closing, our results, for the first time, demonstrate that PPARγ is a critical regulator of
endochondral cartilage health and physiology in early growth and development.
Collectively, our results demonstrate that PPARγ plays a pivotal role in coordinating
diverse aspects of skeletal morphogenesis. A better understanding of the role of PPARγ in
cartilage biology will enable us to devise appropriate PPARγ related therapeutic strategies
against diseases such as OA and related disorders.
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Figure 1.

Characterization of cartilage-specific PPARγ KO mice. (A) Genotyping confirmed presence
of Cre transgene in P0 heterozygote and homozygote KO mice and its absence in control
mice. PPARγ KO band was detected at 230 bps, WT band was detected at ~200 bps, and
Cre band was detected at 700 bps. (B) Western blotting performed on isolated chondrocytes
demonstrated reduced expression and complete absence of PPARγ in heterozygote and
homozygote PPARγ KO mice, respectively, compared to control mice. (C) RT-PCR on
isolated chondrocytes confirmed reduction of PPARγ mRNA levels by >96% in
homozygote PPARγ KO mice compared to control mice. Representative data from n=6
independent isolated chondrocytes per group. Bar graph shows mean +/− SEM of each
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group. *, P<0.05 (D) IHC studies confirmed the absence of PPARγ expression in resting
and hypertrophic chondrocytes of P0 homozygote PPARγ KO mice compared to control
mice. n=4 per group (bar, 100 µm). Figures show one representative experiment of at least
four independent experiments.
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Figure 2.

Cartilage-specific PPARγ KO mice exhibit reduced growth. (A) Newborn homozygote
PPARγ KO mice exhibited growth retardation compared to control mice. (B) Skeletal
staining demonstrated reduced skeletal size (bar, 10 mm) and length of long bones (bar, 1
mm) in homozygote PPARγ KO mice compared to control mice. Arrows indicate loss of
skeletal staining in homozygote PPARγ KO mice. (C) Body length and (D) weight
measurements of P0, P10, P21, and P42 mice demonstrated that homozygote PPARγ KO
mice exhibit delayed growth compared to control mice. (E) Measurements of P0 mice
demonstrated that homozygote PPARγ KO mice have reduced length of tibiae and femurs
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compared to control mice. n=6 per group. Figures show one representative experiment of six
independent experiments. Bar graph shows mean +/− SEM of each group. *, P<0.05
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Figure 3.

Cartilage-specific PPARγ KO mice exhibit delayed ossification and disorganization of
growth plates. (A) Safranin-O/Fast Green staining demonstrated that E16.5 homozygote
PPARγ KO mice exhibit delayed primary ossification compared to control mice. n=6 per
group (bar, 500 µm). (B) Safranin-O/Fast Green staining showed delayed secondary
ossification in the femurs of P14 homozygote PPARγ KO mice compared to control mice.
n=4 per group (bar, 200 µm). (C) Homozygote PPARγ KO growth plates showed
disorganization with reduced cellularity in all the three zones loss of columnar organization
in the proliferating zone and a shorter hypertrophic zone with altered chondrocyte shape
compared to control mice. n=6 per group (bar, 100 µm). (D) Bar graphs show reduced
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cellularity in the resting, proliferating, and hypertrophic zones, and shortened hypertrophic
zone in homozygote PPARγ KO mice compared to control mice. Figures show one
representative experiment of at least four independent experiments. Bar graphs show mean
+/− SEM of each group. *, P<0.05
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Figure 4.

Cartilage-specific PPARγ KO mice exhibit reduced chondrocyte proliferation,
differentiation, hypertrophy and vascular invasion. Staining for (A) Sox9, (B) BrdU, (C)
p57, and (D) collagen type X demonstrated reduced chondrocyte proliferation,
differentiation and hypertrophy in E16.5 homozygote PPARγ KO mouse femurs compared
to control mice. Bar graphs corresponding to IHC analysis show reduced percentage of
positive cells for Sox9, BrdU, p57, and collagen type X in homozygote PPARγ KO mice
compared to control mice (bar, 200µm). (E) IHC for PECAM confirmed reduced vascularity
in the femurs of E16.5 homozygote PPARγ KO mice compared to control mice (bar,
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200µm). n=4 per group. Figures show one representative experiment of four independent
experiments. Bar graphs show mean +/− SEM of each group. * P<0.05
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Figure 5.

Cartilage-specific PPARγ KO mice exhibit decreased calcium deposition, bone density and
trabecular bone thickness. (A) Von Kossa staining of P0 mouse femurs showed that
homozygote PPARγ KO mice exhibit reduced calcium deposition compared to control mice
(bar, 500 µm). (B) Goldner staining and (C) bone density quantification using Bioquant
Osteo II software demonstrated that the femurs of PO homozygote PPARγ KO mice show
decreased bone density compared to control mice (bar, 500 µm). (D) Quantification of
trabecular bone thickness using Bioquant Osteo II software demonstrated that P40 and P70
homozygote PPARγ KO mice exhibit decreased trabecular bone thickness compared to
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control mice. n=4 per group. Figures show one representative experiment of four
independent experiments. Bar graphs show mean +/− SEM of each group. *, P<0.05
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Figure 6.

Genetic ablation of PPARγ results in aberrant expression of endochondral ossification
markers, ECM genes and p38 phosphorylation. (A) mRNA expression using RNA isolated
from E16.5 mouse chondrocytes indicated decreased expression of aggrecan, collagen type
II and SOX9, and increased expression of MMP-13 in homozygote PPARγ KO mice
compared to control mice. (B) mRNA expression using RNA isolated from femur head
cartilage explants of 3 weeks old mice also indicated decreased expression of aggrecan,
collagen type II and SOX9, and increased expression of MMP-13 in homozygote PPARγ
KO mice compared to control mice. (C) Increased phosphorylation of p38 was observed in
E16.5 mouse chondrocytes isolated from homozygote PPARγ KO mice compared to control
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mice. Representative blot from n=4 separate blots is shown. (D) Reduced mRNA expression
of Ihh was observed in E16.5 mouse chondrocytes isolated from homozygote PPARγ KO
mice compared to control mice. Representative data from n=6 independent isolated
chondrocytes and cartilage explants experiments per group. Bar graphs throughout figure
show mean +/− SEM of each group. *, P<0.05
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